Study of Enfuvirtide in HIV-Positive Subjects

Status:

COMPLETED

Study of Enfuvirtide in HIV-Positive Subjects

Lead Sponsor:

Trimeris

Collaborating Sponsors:

Hoffmann-La Roche

Conditions:

HIV Infections

AIDS

Eligibility:

All Genders

18-64 years

Phase:

PHASE1

Brief Summary

A total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. There will be a 7-day washout between doses and a 7-10 day follow-up period.

Eligibility Criteria

Inclusion

Exclusion

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT00086710

Last Update

June 24 2005

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)